The Votes Are In! Our 2018 OutSmarting Osteosarcoma $100,000 award goes to Dr. Matteo Trucco of the University of Miami Sylvester Comprehensive Cancer Center!
This award is made up of many small and not-so-small donations raised in honor and in memory of OsteoWarriors everywhere – it is raised by all of us with 100% of every dollar going to fund this annual award. The recipient is also chosen by this OsteoCommunity – starting with the stakeholders (who have raised or donated $5k or more) coming up with the finalists along with our Scientific Advisory Team, and then voted on by all attendees of the FACTOR conference
We presented a check to Dr. Trucco at the Sylvester Comprehensive Cancer Center in Miami. The names on the check are those in whose honor or memory $5k was raised or donated:
#BecauseOfDylan – Dylan Ip-Toma
#BecasueOfConner – Conner Crossan
#BecauseOfCheyenne – Cheyenne DeVelasco
#BecauseOfSebastian – Sebastian Garcia
#BecauseOfJoshua – Joshua Segal
#BecauseOfJack – Jack Pessaud
#BecauseOfOlivia – Olivia Egge
#BecauseOfVictoria – Victoria Marsh
#BecauseOfMohan – Mohan Anand
#BecauseOfIan – Ian Vallejo
#BecauseOfOwen – Owen Wicks
It is for these and all OsteoWarriors and OsteoAngels we continue to work to Make It Better.
This funding cycle, the OutSmarting Osteosarcoma Team received the most exciting research to review and vote on! The MIB Agents Stakeholders and Scientific Advisory Team were truly excited by the proposals submitted. Everyone in the osteosarcoma community should know and be proud of the intelligent and wholehearted efforts to Make It Better for families facing this diagnosis and metastasis by everyone who submitted their work for consideration. We are honored and grateful for the many physicians and researchers who shared their work with us. We are very grateful for their work on defeating osteosarcoma.
Ballots were sent to ALL FACTOR 2018 ATTENDEES for their vote. The winner will be visited by an MIB Agent Team of OsteoWarriors and a check will be presented. The winner will be the Keynote Speaker at FACTOR 2019.
Our finalists are listed in no particular order:
Thank you to our Stakeholders, Laura Chlopecki, The Crossan Family, The DeVelasco Family, the Douglas Family, The Dyer Family, The Egge Family, The Higgins Family, The Ip-Toma Family, The Jeffries Family, The Marsh Family, The Ortiz Family, The Rajagopalan Family, Paul Romness, The Smith Family, The Vallejo Family, The VanScott Family and The Westenhofer Family, The Segal Family and Joan Susie.
Peter Anderson, MD
He graduated summa cum laude from University of Minnesota, then began an MD, PhD program. This was completed at Mt. Sinai School of Medicine and City University of New York (Biochemical Genetics). Anderson then did a combined Internal Medicine/Pediatrics residency at Duke and Fellowship in Peds Heme/Onc/BMT at University of Minnesota – where he had a lab and obtained 3 patents. He then spent 10 years at Mayo (promoted to Professor) and was involved in some innovative osteosarcoma clinical trials including use of samarium. He was at MD Anderson Cancer Center 2005-2014 and tested mifamurtide, anti-IGFR, samarium, and 223Ra against osteosarcoma. Now at Cleveland Clinic, he remains active in patient advocacy and novel approaches to care of patients with sarcomas, especially osteosarcoma.
Matteo Trucco, MD
Dr. Matteo Trucco received his training in Pediatric Hematology/Oncology from Johns Hopkins University and the National Cancer Institute and has focused his career primarily on Pediatric Sarcomas and the development of new therapies. As the Director of the Pediatric Phase 1 Program at the University of Miami-Sylvester Comprehensive Cancer Center he seeks to identify novel approaches to treating Pediatric Sarcomas, with a particular interest in targeting sarcomas’ metabolism, their hypoxic areas and sarcoma stem cells. He jumped at the opportunity to help bring together researchers, clinicians, patients and advocates as part of the FACTOR conference to stimulate innovation and collaboration to advance the research and treatment of Osteosarcoma.
Rosandra Kaplan, MD
Dr. Kaplan is a physician scientist who developed the concept of the pre-metastatic niche describing the changes in distant microenvironments in response to a growing tumor that create a niche environment conducive to disseminating tumor cell survival and growth resulting in clinically relevant metastasis. Dr. Kaplan has an active translational research program focusing on developing novel biomarkers and targets of the metastatic microenvironment by understanding the commonalities in mechanisms employed by a cancer cell to generate an entire heterogenous tumor at distant sites and stem cells and their niche to repopulate tissues.
Damon R. Reed, MD
Dr. Damon Reed is the Director of the Adolescent and Young Adult Program at Moffitt, the Medical Director of the Sarcoma Department at Moffitt Cancer Center and an Assistant Professor of Pediatrics at the University of South Florida. He is also an on staff as a specialty physician at All Children’s Hospital in St. Petersburg, FL. He is also the Leader of the Pediatric Cancer Foundation’s pediatric phase I consortium, the Sunshine Project. A graduate of Case Western Reserve University School of Medicine in Cleveland, OH, Dr. Reed served a combined pediatric residency program at Boston Children’s Hospital-Harvard Medical School and Boston Medical Center-Boston University School of Medicine. He completed his fellowship training in pediatric hematology/oncology at St. Jude Children’s Research Hospital. He received the CWRU Medical Alumni Association Board of Trustees Award for Outstanding Service and Contributions to the School of Medicine and was named to the Alpha Omega Alpha Honor Medical Society. Dr. Reed is a member of several professional associations, including the American Association for Cancer Research, Connective Tissue Oncology Society and American Society of Clinical Oncology. He joined Moffitt in 2008.
Ramy Ibrahim, MD
Ramy Ibrahim, MD, is a recognized leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. Dr. Ibrahim currently serves as vice president of clinical development at the Parker Institute for Cancer Immunotherapy. Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as the Society of Immunotherapy for Cancer (SITC), Ludwig Institute, the Cancer Research Institute and Cancer Immunotherapy Trials Network (CITN). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.